Nebenwirkungen · Reagila
Reagila 1.5 mg hard capsules Reagila 3 mg hard capsules Reagila 4.5 mg hard capsules Reagila 6 mg hard capsules · Abschnitt 4.8 · PDF-Seite 11
HOS-129571 · Präparat HOS-096751
In the negative symptom study EPS was reported in 14.3% in the cariprazine group and 11.7% in the risperidone treated patients. Akathisia was reported in 10.0% in patients treated with cariprazine and 5.2% in the risperidone group. Parkinsonism was experienced in 5.2% and 7.4% in cariprazine and risperidone treated patients respectively. Most EPS cases were mild to moderate in intensity and could be handled with common anti-EPS medicinal products. The rate of discontinuation due to EPS related ADRs was low.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T14:49:00Z · SHA-256 9d13d908e239f6368505bfcde6e4381ffb6295f6bc6de049f006e4abed967ec2 · Passage 97ed97eee9bec3b6afafce820988a2ccd2146ece2c1f3dbfcec2e728c55b7bbc · Zeichen 9222–9734 im Abschnitt